Sneha Kollenchery Ramanathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sneha Kollenchery Ramanathan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Aleksandra Zielińska
Experimental Plastic Surgery Department of Biomedical and Clinical Sciences Linköping University Hospital Linköping 581 83 Sweden
1 shared publicationAnnika Starkenberg
Experimental Plastic Surgery Department of Biomedical and Clinical Sciences Linköping University Hospital Linköping 581 83 Sweden
1 shared publication- Daniel Aili
Laboratory of Molecular Materials, Division of Biophysics and Bioengineering, Department of Physics, Chemistry and Biology, Linköping University, SE-581 83, Linköping, Sweden
1 shared publication - Fatemeh Rasti Boroojeni
Laboratory of Molecular Materials Division of Biophysics and Bioengineering Department of Physics, Chemistry and Biology Linköping University Linköping 581 83 Sweden
1 shared publication - Gunnar Kratz
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
1 shared publication - Johan P. E. Junker
Center for Disaster Medicine and Traumatology, Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85, Linköping, Sweden
1 shared publication
Latest Publications
- Open Access
- 12 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (21) , e2501430
Biphasic Granular Bioinks for Biofabrication of High Cell Density Constructs for Dermal Regeneration
Chronic wounds and severe skin injuries pose significant clinical challenges, as existing treatments like cultured epidermal autografts and tissue engineering strategies fail to regenerate functional dermal tissue effectively. These methods often result in scarring due to poor tissue integration, low cell density, and limited extracellular matrix (ECM) production. Conventional skin tissue engineering relies on time‐intensive cell expansion, producing constructs that lack the complexity of native dermal structures. Here, a bioprintable biphasic granular hydrogel bioink (µInk) based on cell‐laden porous gelatin microcarriers (PGMs) is presented, enabling fabrication of ultra‐high cell density constructs that promote ECM production for dermal regeneration in vitro and in vivo. Primary human dermal fibroblasts are cultured and expanded on PGMs in a bioreactor prior µInk formulation. The cell‐laden PGMs are cross‐linked via copper‐free click chemistry, creating a shear‐thinning granular bioink. The µInk is 3D bioprinted into structurally stable constructs with high cell viability. In vivo, the bioprinted constructs supported neovascularization, hydrogel remodeling, and tissue integration over 28 days. Cells maintained their tissue‐specific phenotype, proliferated, and produced dermal ECM post‐transplantation. The µInk offers a promising approach to generating high cell‐density constructs for scar‐free wound healing and for advancing complex tissue reconstruction.
- 12 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (21) , e2501430
Open AccessBiphasic Granular Bioinks for Biofabrication of High Cell Density Constructs for Dermal Regeneration
Chronic wounds and severe skin injuries pose significant clinical challenges, as existing treatments like cultured epidermal autografts and tissue engineering strategies fail to regenerate functional dermal tissue effectively. These methods often result in scarring due to poor tissue integration, low cell density, and limited extracellular matrix (ECM) production. Conventional skin tissue engineering relies on time‐intensive cell expansion, producing constructs that lack the complexity of native dermal structures. Here, a bioprintable biphasic granular hydrogel bioink (µInk) based on cell‐laden porous gelatin microcarriers (PGMs) is presented, enabling fabrication of ultra‐high cell density constructs that promote ECM production for dermal regeneration in vitro and in vivo. Primary human dermal fibroblasts are cultured and expanded on PGMs in a bioreactor prior µInk formulation. The cell‐laden PGMs are cross‐linked via copper‐free click chemistry, creating a shear‐thinning granular bioink. The µInk is 3D bioprinted into structurally stable constructs with high cell viability. In vivo, the bioprinted constructs supported neovascularization, hydrogel remodeling, and tissue integration over 28 days. Cells maintained their tissue‐specific phenotype, proliferated, and produced dermal ECM post‐transplantation. The µInk offers a promising approach to generating high cell‐density constructs for scar‐free wound healing and for advancing complex tissue reconstruction.